tiprankstipranks
Bellerophon receives IND clearance from China NMPA to conduct Phase 3 trial
The Fly

Bellerophon receives IND clearance from China NMPA to conduct Phase 3 trial

Bellerophon Therapeutics announced clearance of its Investigational New Drug, IND, application from the Center for Drug Evaluation of China’s National Medical Products Administration, NMPA, to conduct a Phase 3 clinical trial to support the registration of INOpulse for the treatment of fibrotic interstitial lung disease, fILD, in China. The study will utilize Moderate to Vigorous Physical Activity, MVPA, as the primary endpoint and be conducted in collaboration with Bellerophon’s regional partner, Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China. "We are delighted to expand our clinical program with the aim of bringing INOpulse to patients in need in Greater China," said Peter Fernandes, Bellerophon’s Chief Executive Officer. "INOpulse has the potential to become the first therapy to treat an fILD population that includes patients at low-, intermediate- and high-risk of pulmonary hypertension. This IND clearance further underscores the potential of INOpulse to improve activities of daily living and quality of life in patients with fILD, and supports the use of our novel primary endpoint, MVPA, which we are also utilizing in our ongoing Phase 3 REBUILD study in the U.S."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on BLPH:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles